Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response (Q61690623)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 November 2007

Language	Label	Description	Also known as
English	Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response	scientific article published on 29 November 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

molecular medicine

0 references

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

María Colmenares

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Alonso A

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Marcen JM

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Peris A

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Castillo JA

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Larraga V

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

0 references

publication date

29 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

333-344

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Leishmaniasis in Sardinia: II. Natural infection of Phlebotomus perniciosus Newstead, 1911, by Leishmania infantum Nicolle, 1908, in the province of Cagliari.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

The immunology of canine leishmaniosis: strong evidence for a developing disease spectrum from asymptomatic dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Canine leishmaniasis: identification of asymptomatic carriers by polymerase chain reaction and immunoblotting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Prevalence of Leishmania infantum infection in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Chemotherapy of leishmaniasis: past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Macrophage activation by interferon-gamma from host-protective T cells is inhibited by interleukin (IL)3 and IL4 produced by disease-promoting T cells in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

The in vitro Generation and Functional Analysis of Murine T Cell Populations and Clones Specific for a Protozoan Parasite, Leishmania tropica

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Expression cloning of a protective Leishmania antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Demonstration of Leishmania specific cell mediated and humoral immunity in asymptomatic dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Immunology of canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Cytokine expression during the outcome of canine experimental infection by Leishmania infantum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

An experimental model for canine visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Infectivity of promastigotes and amastigotes of Leishmania infantum in a canine model for leishmaniosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Canine leishmaniasis: epidemiological risk and the experimental model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Analysis of the humoral immune response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

A follow-up of Beagle dogs intradermally infected with Leishmania chagasi in the presence or absence of sand fly saliva

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

IgG subclass responses in a longitudinal study of canine visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Immunoglobulin G and E responses in various stages of canine leishmaniosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Cell mediated immunity and specific IgG1 and IgG2 antibody response in natural and experimental canine leishmaniosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Anti-Leishmania humoral and cellular immune responses in naturally infected symptomatic and asymptomatic dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Flow cytometric analysis of cellular immune responses in dogs experimentally infected with a North American isolate of Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Detection of canine cytokine gene expression by reverse transcription-polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between splenic and lymph node aspirations as sampling methods for the parasitological detection of Leishmania chagasi infection in dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.021

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.11.021

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18093705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61690623&oldid=2127539041"